PharmaNutra participates in the Italian Mid Cap Conference 2021

The third edition of the Italian Mid Cap Conference, organised by Mediobanca officially opened yesterday, seeing the participation of top companies, including PharmaNutra.

“New drivers of growth – the opportunity for change ”, this is the central theme of the two days of Italian Mid Cap Conference, in which 140 international investors will meet online with 25 Italian mid-capitalization companies to evaluate development plans.

The agenda of one-to-one meetings between companies and investors is closed, but it will also leave room for a plenary session during which Mediobanca and the companies will meet to discuss growth drivers in a moment of great change, with a special focus on sustainable development and special operations in the era of Covid.

An important occasion for PharmaNutra to officially introduce themselves to the Italian corporate world and new investors, institutional and private, after the recent transfer of shares from the AIM market to the MTA market – STAR segment of the Borsa Italiana [Italian Stock Exchange].

“The Italian Mid Cap Conference is a particularly stimulating meeting for PharmaNutra, given the presence of new national and international investors who have already shown significant interest in our company. This is already the first positive effect of our transfer to the STAR segment of the MTA market”, commented Roberto Lacorte, Vice-President of PharmaNutra S.p.A. “As well as being a major business opportunity, the Conference organised by Mediobanca is also a reason for great satisfaction, because we will have the opportunity to personally present our history and company growth, as well as illustrate prospects for the future. We hope to transmit this enthusiasm and confidence in those who meet us for the first time as investors”.

During the Italian Mid Cap Conference 2021, PharmaNutra, together with the President Andrea Lacorte, the Vice-President Roberto Lacorte, the COO Carlo Volpi and the CFO Francesco Sarti, will illustrate to the investors the main drivers behind the Group’s growth strategy over the last three decades. Growth that also in 2020, despite the Covid-19 pandemic, has been confirmed both by financial results and market data from the first semester, made official by FederSalus.
Meanwhile, as regards the medium-long term, the development plans of PharmaNutra are closely tied to global commercial expansion and continuous investments in research and development, which will enable the Group to strengthen its current position on the market and expand its core business in the neutraceutical and pharmaceutical sectors.